Interaction/NN
Effects/NNS
of/IN
Lipoprotein/NN
Lipase/NN
Polymorphisms/NNS
with/IN
Lifestyle/JJ
on/IN
Lipid/NN
Levels/NNS
in/IN
a/DT
Korean/JJ
Population/NN
:/:
A/DT
Cross-sectional/JJ
Study/NN
./.
====================
Lipoprotein/NN
lipase/NN
(/(
LPL/NN
)/)
plays/VBZ
an/DT
essential/JJ
role/NN
in/IN
the/DT
regulation/NN
of/IN
high-density/JJ
lipoprotein/NN
cholesterol/NN
(/(
HDLC/NN
)/)
and/CC
triglyceride/NN
levels/NNS
,/,
which/WDT
have/VBP
been/VBN
closely/RB
associated/VBN
with/IN
cardiovascular/JJ
diseases/NNS
./.
====================
Genetic/JJ
studies/NNS
in/IN
European/JJ
have/VBP
shown/VBN
that/IN
LPL/NN
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
are/VBP
strongly/RB
associated/VBN
with/IN
lipid/NN
levels/NNS
./.
====================
However/RB
,/,
studies/NNS
about/IN
the/DT
influence/NN
of/IN
interactions/NNS
between/IN
LPL/NN
SNPs/NNS
and/CC
lifestyle/JJ
factors/NNS
have/VBP
not/RB
been/VBN
sufficiently/RB
performed/VBN
./.
====================
Here/RB
,/,
we/PRP
examine/VBP
if/IN
LPL/NN
polymorphisms/NNS
,/,
as/IN
well/RB
as/IN
their/PRP$
interaction/NN
with/IN
lifestyle/JJ
factors/NNS
,/,
influence/VBP
lipid/NN
concentrations/NNS
in/IN
a/DT
Korean/JJ
population/NN
./.
====================
A/DT
two-stage/JJ
association/NN
study/NN
was/VBD
performed/VBN
using/VBG
genotype/JJ
data/NNS
for/IN
SNPs/NNS
on/IN
the/DT
LPL/NN
gene/NN
,/,
including/VBG
the/DT
3/CD
'/``
flanking/JJ
region/NN
from/IN
7,536/CD
(/(
stage/NN
1/CD
)/)
and/CC
3,703/CD
(/(
stage/NN
2/CD
)/)
individuals/NNS
./.
====================
The/DT
association/NN
study/NN
showed/VBD
that/IN
15/CD
SNPs/NNS
and/CC
4/CD
haplotypes/NNS
were/VBD
strongly/RB
associated/VBN
with/IN
HDLC/NN
(/(
lowest/JJS
p/NN
=/JJ
2.86/CD
×/CD
10-22/CD
)/)
and/CC
triglyceride/NN
levels/NNS
(/(
lowest/JJS
p/NN
=/JJ
3.0/CD
×/CD
10-15/CD
)/)
./.
====================
Interactions/NNS
between/IN
LPL/NN
polymorphisms/NNS
and/CC
lifestyle/JJ
factors/NNS
(/(
lowest/JJS
p/NN
=/JJ
9.6/CD
×/CD
10-4/CD
)/)
were/VBD
also/RB
observed/VBN
on/IN
lipid/NN
concentrations/NNS
./.
====================
These/DT
findings/NNS
suggest/VBP
that/IN
there/EX
are/VBP
interaction/NN
effects/NNS
of/IN
LPL/NN
polymorphisms/NNS
with/IN
lifestyle/JJ
variables/NNS
,/,
including/VBG
energy/NN
intake/JJ
,/,
fat/JJ
intake/JJ
,/,
smoking/VBG
,/,
and/CC
alcohol/NN
consumption/NN
,/,
as/IN
well/RB
as/IN
effects/NNS
of/IN
LPL/NN
polymorphisms/NNS
themselves/DT
,/,
on/IN
lipid/NN
concentrations/NNS
in/IN
a/DT
Korean/JJ
population/NN
./.
====================
Lipoprotein/NN
lipase/NN
(/(
LPL/NN
)/)
plays/VBZ
an/DT
important/JJ
role/NN
in/IN
the/DT
metabolism/NN
and/CC
transport/VBP
of/IN
lipids/NNS
./.
====================
It/PRP
hydrolyzes/VBZ
triglycerides/VBZ
(/(
TGs/NNS
)/)
in/IN
lipoproteins/NNS
,/,
such/JJ
as/IN
chylomicrons/NNS
(/(
CMs/NNS
)/)
and/CC
very/RB
low-density/JJ
lipoproteins/NNS
(/(
VLDLs/NNS
)/)
,/,
into/IN
free/JJ
fatty/JJ
acids/NNS
,/,
releasing/VBG
CM/NN
remnants/VBZ
and/CC
intermediate-density/NN
lipoproteins/NNS
that/IN
act/VBP
on/IN
high-density/JJ
lipoprotein/NN
cholesterol/NN
(/(
HDLC/NN
)/)
metabolism/NN
./.
====================
Plasma/NN
LPL/NN
therefore/RB
plays/VBZ
an/DT
essential/JJ
role/NN
in/IN
elevating/VBG
HDLC/NN
and/CC
lowering/JJ
TG/NN
[/(
1-3/CD
]/)
./.
====================
While/IN
HDLC/NN
plays/VBZ
a/DT
role/NN
in/IN
the/DT
removal/NN
and/CC
transport/VBP
of/IN
cholesterol/NN
from/IN
peripheral/JJ
tissues/NNS
to/TO
other/JJ
tissues/NNS
where/WRB
it/PRP
is/VBZ
required/VBN
,/,
such/JJ
as/IN
the/DT
liver/NN
,/,
low-density/JJ
lipoprotein/NN
cholesterol/NN
(/(
LDLC/NN
)/)
is/VBZ
,/,
conversely/RB
,/,
transported/VBN
from/IN
the/DT
liver/NN
to/TO
peripheral/JJ
tissues/NNS
./.
====================
The/DT
concentration/NN
of/IN
lipids/NNS
has/VBZ
been/VBN
tightly/RB
associated/VBN
with/IN
the/DT
risk/NN
of/IN
cardiovascular/JJ
diseases/NNS
[/(
4-6/CD
]/)
./.
====================
Specifically/RB
,/,
LDLC/NN
levels/NNS
have/VBP
been/VBN
shown/VBN
to/TO
have/VB
a/DT
positive/JJ
log-linear/JJ
association/NN
with/IN
the/DT
risk/NN
of/IN
coronary/JJ
heart/NN
disease/NN
:/:
a/DT
reduction/NN
of/IN
1/CD
%/NN
in/IN
the/DT
serum/NN
concentration/NN
of/IN
LDLC/NN
has/VBZ
been/VBN
shown/VBN
to/TO
reduce/VB
the/DT
relative/JJ
risk/NN
of/IN
coronary/JJ
heart/NN
disease/NN
risk/NN
by/IN
approximately/RB
1/CD
%/NN
[/(
7/CD
]/)
,/,
whereas/IN
an/DT
increase/NN
of/IN
1/CD
mg/dL/NN
in/IN
serum/NN
HDLC/NN
levels/NNS
is/VBZ
associated/VBN
with/IN
a/DT
decrease/NN
in/IN
the/DT
risk/NN
of/IN
coronary/JJ
heart/NN
disease/NN
of/IN
approximately/RB
2/CD
%/NN
to/TO
3/CD
%/NN
,/,
independent/JJ
of/IN
LDLC/NN
levels/NNS
[/(
8/CD
]/)
./.
====================
It/PRP
was/VBD
also/RB
reported/VBD
that/IN
TG/NN
levels/NNS
are/VBP
associated/VBN
with/IN
risk/NN
of/IN
cardiovascular/JJ
disease/NN
,/,
independent/JJ
of/IN
concentrations/NNS
of/IN
other/JJ
lipids/NNS
and/CC
cardiac/JJ
risk/NN
factors/NNS
,/,
although/IN
there/EX
has/VBZ
been/VBN
controversy/NN
[/(
6/CD
]/)
./.
====================
Recently/RB
,/,
a/DT
report/NN
based/VBN
on/IN
the/DT
Korea/NN
National/JJ
Health/NN
and/CC
Nutrition/NN
Examination/NN
Surveys/NNS
I/NN
,/,
II/CD
,/,
III/CD
,/,
and/CC
IV/CD
has/VBZ
indicated/VBN
that/IN
the/DT
prevalence/NN
of/IN
dyslipidemia/NN
and/CC
hypertriglyceridemia/NN
in/IN
this/DT
country/NN
has/VBZ
increased/VBN
during/IN
the/DT
last/JJ
decade/NN
[/(
9/CD
]/)
./.
====================
Genetic/JJ
association/NN
studies/NNS
aimed/VBD
at/IN
identifying/VBG
the/DT
genetic/JJ
factors/NNS
associated/VBN
with/IN
variations/NNS
in/IN
lipid/NN
concentrations/NNS
have/VBP
been/VBN
performed/VBN
mostly/RB
for/IN
Europeans/NNS
,/,
and/CC
they/PRP
have/VBP
shown/VBN
that/IN
the/DT
polymorphisms/NNS
in/IN
the/DT
LPL/NN
gene/NN
,/,
including/VBG
the/DT
3/CD
'/``
flanking/JJ
region/NN
,/,
are/VBP
strongly/RB
associated/VBN
with/IN
HDLC/NN
and/CC
TG/NN
levels/NNS
[/(
10-13/CD
]/)
./.
====================
There/EX
is/VBZ
a/DT
report/NN
of/IN
a/DT
candidate/NN
gene/NN
approach/NN
for/IN
lipid/NN
concentrations/NNS
in/IN
a/DT
Korean/JJ
population/NN
,/,
but/CC
the/DT
LPL/NN
gene/NN
was/VBD
not/RB
included/VBN
in/IN
the/DT
study/NN
[/(
14/CD
]/)
./.
====================
The/DT
concentration/NN
of/IN
lipids/NNS
is/VBZ
also/RB
influenced/VBD
by/IN
environmental/JJ
factors/NNS
,/,
such/JJ
as/IN
smoking/NN
,/,
alcohol/NN
consumption/NN
,/,
diet/VBP
,/,
and/CC
physical/JJ
activity/NN
,/,
as/IN
well/RB
as/IN
genetic/JJ
factors/NNS
[/(
5/CD
,/,
15/CD
]/)
./.
====================
However/RB
,/,
studies/NNS
about/IN
the/DT
influence/NN
of/IN
interactions/NNS
between/IN
LPL/NN
polymorphisms/NNS
and/CC
lifestyle/JJ
factors/NNS
have/VBP
not/RB
been/VBN
sufficiently/RB
performed/VBN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
examined/VBD
the/DT
effects/NNS
of/IN
potential/JJ
interactions/NNS
between/IN
LPL/NN
polymorphisms/NNS
and/CC
lifestyle/JJ
,/,
as/IN
well/RB
as/IN
genetic/JJ
variations/NNS
of/IN
the/DT
LPL/NN
gene/NN
,/,
including/VBG
the/DT
3/CD
'/``
flanking/JJ
region/NN
,/,
on/IN
the/DT
lipid/NN
profile/NN
of/IN
a/DT
Korean/JJ
population/NN
./.
====================
Subjects/NNS
====================
Data/NNS
for/IN
this/DT
study/NN
were/VBD
obtained/VBN
from/IN
the/DT
Korean/JJ
Genome/NN
Epidemiology/NN
Study/NN
(/(
KoGES/NN
)/)
,/,
conducted/VBN
by/IN
the/DT
Korean/JJ
National/JJ
Institute/JJ
of/IN
Health/NN
(/(
KNIH/NN
)/)
./.
====================
The/DT
study/NN
comprised/VBD
two/CD
stages/NNS
./.
====================
In/IN
the/DT
first/JJ
stage/NN
,/,
a/DT
cross-sectional/JJ
analysis/NN
was/VBD
conducted/VBN
of/IN
samples/NNS
from/IN
urban/JJ
and/CC
rural/JJ
communities/NNS
from/IN
South/NN
Korea/NN
,/,
whereas/IN
in/IN
the/DT
second/JJ
stage/NN
,/,
the/DT
study/NN
was/VBD
replicated/VBN
in/IN
other/JJ
urban/JJ
regions/NNS
in/IN
Korea/NN
./.
====================
Subjects/NNS
who/WP
were/VBD
examined/VBN
in/IN
the/DT
first/JJ
stage/NN
,/,
described/VBN
in/IN
a/DT
previous/JJ
report/NN
[/(
16/CD
]/)
,/,
were/VBD
recruited/VBN
from/IN
a/DT
rural/JJ
(/(
Ansung/JJ
)/)
and/CC
an/DT
urban/JJ
(/(
Ansan/NNP
)/)
community/NN
from/IN
South/DT
Korea/NN
,/,
which/WDT
have/VBP
been/VBN
studied/VBN
since/IN
2001/CD
as/IN
a/DT
part/NN
of/IN
KoGES/NN
./.
====================
In/IN
total/JJ
,/,
5,018/CD
and/CC
5,020/CD
subjects/NNS
from/IN
the/DT
Ansung/JJ
and/CC
Ansan/NN
communities/NNS
,/,
respectively/RB
,/,
participated/JJ
in/IN
the/DT
study/NN
./.
====================
The/DT
age/NN
of/IN
the/DT
participants/NNS
ranged/VBD
from/IN
40/CD
to/TO
69/CD
years/NNS
./.
====================
Samples/NNS
were/VBD
scrutinized/VBN
for/IN
quality/NN
control/NN
purposes/NNS
,/,
after/IN
which/WDT
8,842/CD
subjects/NNS
remained/VBD
in/IN
our/PRP$
sample/NN
[/(
16/CD
]/)
./.
====================
We/PRP
further/RB
excluded/VBN
1,306/CD
subjects/NNS
who/WP
were/VBD
on/IN
medication/NN
for/IN
hypertension/NN
,/,
diabetes/VBZ
,/,
myocardial/JJ
infarction/NN
,/,
and/CC
hyperlipidemia/NN
./.
====================
Information/NN
about/RB
the/DT
lifestyle/JJ
of/IN
the/DT
subjects/NNS
was/VBD
based/VBN
on/IN
their/PRP$
responses/NNS
to/TO
questionnaires/NNS
./.
====================
For/IN
the/DT
second/JJ
stage/NN
of/IN
the/DT
study/NN
,/,
4,302/CD
samples/NNS
were/VBD
obtained/VBN
from/IN
both/DT
urban/JJ
regions/NNS
,/,
Seoul/JJ
and/CC
Busan/NN
,/,
in/IN
South/NN
Korea/NN
that/DT
were/VBD
established/VBN
from/IN
2006/CD
to/TO
2007/CD
as/IN
part/NN
of/IN
KoGES/NN
./.
====================
Samples/NNS
satisfying/JJ
any/DT
of/IN
the/DT
following/VBG
criteria/NNS
were/VBD
excluded/VBN
:/:
i/LS
)/)
gender/RB
inconsistencies/VBZ
,/,
ii/LS
)/)
genotype/NN
call/JJ
rate/NN
lower/JJR
than/IN
95/CD
%/NN
,/,
iii/LS
)/)
excessive/JJ
heterozygosity/NN
,/,
iv/LS
)/)
cryptic/JJ
first/JJ
degree/NN
relative/JJ
,/,
v/LS
)/)
outliers/VBZ
on/IN
a/DT
multidimensional/JJ
scaling/VBG
plot/NN
,/,
or/CC
vi/FW
)/)
cancer/NN
history/JJ
./.
====================
A/DT
total/JJ
of/IN
3,703/CD
subjects/NNS
remained/VBD
in/IN
our/PRP$
sample/NN
./.
====================
These/DT
exclusion/NN
criteria/NNS
for/IN
samples/NNS
have/VBP
been/VBN
described/VBN
[/(
17/CD
]/)
./.
====================
Details/NNS
of/IN
the/DT
sample/NN
characteristics/NNS
are/VBP
listed/VBN
in/IN
Table/JJ
1/CD
./.
====================
Genotyping/VBG
====================
We/PRP
obtained/VBD
genotype/NN
data/NNS
for/IN
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
located/JJ
in/IN
the/DT
LPL/NN
gene/NN
,/,
including/VBG
the/DT
3/CD
'/``
flanking/JJ
region/NN
,/,
from/IN
KoGES/NN
,/,
which/WDT
are/VBP
accessible/JJ
to/TO
the/DT
research/NN
community/NN
through/IN
the/DT
Korean/JJ
Associated/VBN
Resource/NN
project/VB
./.
====================
The/DT
study/NN
protocol/NN
was/VBD
approved/VBN
by/IN
the/DT
Institutional/JJ
Review/NN
Board/JJ
of/IN
KNIH/NN
./.
====================
For/IN
genotyping/VBG
of/IN
the/DT
samples/NNS
from/IN
the/DT
Ansung/JJ
and/CC
Ansan/NN
cohorts/NNS
,/,
Affymetrix/JJ
Genome-Wide/NN
Human/JJ
SNP/NN
Array/NN
5.0/CD
(/(
Affymetrix/JJ
Inc./NNP
,/,
Santa/NN
Clara/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
was/VBD
used/VBN
./.
====================
Affymetrix/JJ
Genome-Wide/NN
Human/JJ
SNP/NN
Array/NN
6.0/CD
(/(
Affymetrix/JJ
Inc./NNP
)/)
was/VBD
used/VBN
for/IN
genotyping/VBG
samples/NNS
from/IN
the/DT
Seoul/JJ
and/CC
Busan/NN
cohorts/NNS
./.
====================
The/DT
Bayesian/JJ
Robust/NNP
Linear/JJ
Model/NN
with/IN
the/DT
Mahalanobis/NN
distance/NN
algorithm/NN
was/VBD
used/VBN
to/TO
determine/VB
the/DT
genotypes/NNS
at/IN
each/DT
SNP/NN
of/IN
Affymetrix/JJ
5.0/CD
./.
====================
The/DT
BirdSeed/JJ
calling/JJ
genotyping/VBG
algorithm/NN
was/VBD
used/VBN
on/IN
Affymetrix/JJ
6.0/CD
./.
====================
The/DT
SNPs/NNS
were/VBD
filtered/VBN
if/IN
any/DT
of/IN
the/DT
following/VBG
criteria/NNS
was/VBD
met/JJ
:/:
i/LS
)/)
a/DT
call/JJ
rate/NN
lower/JJR
than/IN
95/CD
%/NN
,/,
ii/LS
)/)
a/DT
minor/JJ
allele/NN
frequency/NN
(/(
MAF/NN
)/)
lower/JJR
than/IN
0.05/CD
,/,
or/CC
iii/LS
)/)
significant/JJ
deviation/NN
from/IN
the/DT
Hardy-Weinberg/JJ
equilibrium/NN
(/(
HWE/NNP
)/)
./.
====================
Significant/JJ
deviation/NN
from/IN
HWE/NN
for/IN
28/CD
successfully/RB
genotyped/VBN
SNPs/NNS
was/VBD
determined/VBN
based/VBN
on/IN
a/DT
threshold/JJ
of/IN
p/NN
</JJR
0.002/CD
(/(
0.05/28/CD
)/)
./.
====================
SNP/NN
imputation/NN
was/VBD
performed/VBN
using/VBG
the/DT
IMPUTE/NN
program/NN
(/(
https/NNS
:/:
//mathgen.stats.ox.ac.uk/impute/impute.html/NN
)/)
./.
====================
A/DT
reference/VBP
panel/NN
from/IN
International/JJ
HapMap/NN
(/(
phase/NN
II/release/NN
22/NCBI/CD
build/JJ
36/CD
and/CC
dbSNP/NN
build/JJ
126/CD
)/)
data/NNS
,/,
comprising/VBG
SNPs/NNS
from/IN
90/CD
Japanese/JJ
(/(
JPT/NN
)/)
and/CC
Han/JJ
Chinese/JJ
(/(
CHB/NN
)/)
individuals/NNS
,/,
was/VBD
used/VBN
as/IN
a/DT
template/JJ
for/IN
inferring/VBG
untyped/JJ
genotypes/NNS
./.
====================
Imputed/JJ
SNPs/NNS
that/IN
were/VBD
located/JJ
in/IN
the/DT
LPL/NN
gene/NN
,/,
including/VBG
the/DT
3/CD
'/``
flanking/JJ
region/NN
,/,
with/IN
low/JJ
quality/NN
were/VBD
excluded/VBN
according/VBG
to/TO
the/DT
following/VBG
criteria/NNS
:/:
low/JJ
genotype/NN
information/NN
content/NN
(/(
information/NN
lower/JJR
than/IN
0.5/CD
)/)
,/,
a/DT
posterior/JJ
probability/NN
score/RB
lower/JJR
than/IN
0.90/CD
,/,
a/DT
call/JJ
rate/NN
lower/JJR
than/IN
0.95/CD
,/,
and/CC
MAF/NN
lower/JJR
than/IN
0.05/CD
./.
====================
Biochemical/JJ
measures/NNS
====================
Biochemical/JJ
data/NNS
from/IN
KoGES/NN
were/VBD
obtained/VBN
through/IN
the/DT
Korean/JJ
Association/NN
Resource/NN
(/(
KARE/NN
)/)
project/VBP
./.
====================
Blood/NN
samples/NNS
were/VBD
obtained/VBN
from/IN
the/DT
participants/NNS
with/IN
at/IN
least/JJS
8/CD
hours/NNS
of/IN
overnight/JJ
fasting/JJ
./.
====================
Serum/NN
total/JJ
cholesterol/NN
(/(
TCHL/NN
)/)
,/,
HDLC/NN
,/,
and/CC
TG/NN
concentrations/NNS
were/VBD
measured/VBN
using/VBG
the/DT
Advia/NN
1650/CD
analyzer/CC
(/(
Siemens/NNS
,/,
Tarrytown/JJ
,/,
NY/NNP
,/,
USA/NNP
)/)
for/IN
the/DT
Ansung/JJ
and/CC
Ansan/JJ
cohorts/NNS
and/CC
the/DT
Hitachi/NN
7600/CD
analyzer/CC
(/(
Hitachi/NNP
,/,
Tokyo/NNP
,/,
Japan/NNP
)/)
for/IN
the/DT
Seoul/JJ
and/CC
Busan/NNP
study/NN
cohorts/VBZ
[/(
16/CD
,/,
17/CD
]/)
./.
====================
LDLC/NN
concentration/NN
was/VBD
estimated/VBN
using/VBG
the/DT
equation/NN
by/IN
Friedewald/NN
et/FW
al/JJ
./.
====================
[/(
18/CD
]/)
for/IN
individuals/NNS
with/IN
TG/NN
levels/NNS
lower/JJR
than/IN
400/CD
mg/dL/NN
./.
====================
Statistics/NNS
====================
To/TO
test/VB
the/DT
association/NN
between/IN
LPL/NN
SNPs/NNS
and/CC
haplotypes/NNS
(/(
HTs/NNS
)/)
and/CC
lipid/NN
concentration/NN
,/,
linear/JJ
regression/NN
analyses/NNS
,/,
adjusted/VBN
for/IN
age/NN
,/,
gender/RB
,/,
and/CC
body/NN
mass/NN
index/NN
(/(
BMI/NN
)/)
,/,
were/VBD
performed/VBN
./.
====================
For/IN
stage/NN
1/CD
and/CC
imputed/VBD
data/NNS
,/,
the/DT
residence/NN
area/NN
of/IN
each/DT
participant/NN
was/VBD
additionally/RB
adjusted/VBN
./.
====================
The/DT
influence/NN
of/IN
the/DT
interaction/NN
between/IN
LPL/NN
SNPs/NNS
and/CC
lifestyle/JJ
variables/NNS
on/IN
lipid/NN
levels/NNS
was/VBD
analyzed/VBN
by/IN
using/VBG
linear/JJ
regression/NN
,/,
including/VBG
main/JJ
and/CC
interaction/NN
effects/NNS
,/,
adjusted/VBN
for/IN
residence/NN
area/NN
,/,
age/NN
,/,
gender/RB
,/,
and/CC
BMI/NN
./.
====================
The/DT
effect/NN
of/IN
energy/NN
and/CC
fat/NN
intake/NN
,/,
physical/JJ
activity/NN
,/,
smoking/NN
,/,
and/CC
drinking/VBG
status/NN
on/IN
lipid/NN
profiles/NNS
was/VBD
examined/VBN
./.
====================
Energy/NN
intake/JJ
,/,
fat/NN
intake/JJ
,/,
and/CC
physical/JJ
activity/NN
were/VBD
measured/VBN
as/IN
the/DT
total/JJ
intake/NN
of/IN
kilocalories/NNS
per/IN
day/NN
,/,
daily/RB
fat/JJ
intake/JJ
,/,
and/CC
metabolic/JJ
equivalent/JJ
scores/NNS
per/IN
hour/NN
,/,
respectively/RB
./.
====================
Smoking/JJ
status/NN
had/VBD
two/CD
categories/NNS
,/,
non-smokers/NNS
and/CC
smokers/NNS
,/,
and/CC
alcohol/NN
consumption/NN
was/VBD
divided/VBN
into/IN
non-drinkers/NNS
and/CC
drinkers/VBZ
./.
====================
These/DT
lifestyle/JJ
factors/NNS
were/VBD
available/JJ
for/IN
subjects/NNS
from/IN
stage/NN
1/CD
and/CC
imputed/VBD
data/NNS
but/CC
not/RB
from/IN
stage/NN
2/CD
./.
====================
All/DT
analyses/NNS
were/VBD
performed/VBN
by/IN
log-transforming/VBG
HDLC/NN
,/,
TG/NN
,/,
and/CC
TCHL/NN
values/NNS
to/TO
normalize/VB
their/PRP$
distribution/NN
./.
====================
Untransformed/JJ
LDLC/NN
values/NNS
were/VBD
used/VBN
for/IN
all/DT
analyses/NNS
./.
====================
To/TO
determine/VB
the/DT
effect/NN
of/IN
SNPs/NNS
,/,
untransformed/JJ
lipid/NN
concentrations/NNS
were/VBD
used/VBN
./.
====================
Linkage/JJ
disequilibrium/NN
(/(
LD/NN
)/)
block/VBP
partition/NN
was/VBD
performed/VBN
by/IN
Gabriel/JJ
's/POS
rule/JJ
,/,
applied/VBN
in/IN
Haploview/NN
version/NN
4.1/CD
(/(
Broad/JJ
Institute/RB
of/IN
MIT/NN
and/CC
Harvard/JJ
University/JJ
,/,
Boston/NNP
,/,
MA/NN
,/,
USA/NNP
)/)
,/,
and/CC
HT/NN
inference/RB
was/VBD
performed/VBN
using/VBG
the/DT
expectation/NN
maximization/NN
algorithm/NN
with/IN
PLINK/NN
version/NN
1.07/CD
(/(
http/NN
:/:
//pngu.mgh.harvard.edu/~purcell/plink/NN
)/)
./.
====================
All/DT
statistical/JJ
analyses/NNS
were/VBD
performed/VBN
in/IN
an/DT
additive/JJ
model/NN
(/(
AA/NN
vs./CC
AB/LS
vs./CC
BB/NN
or/CC
+/+/JJ
vs./CC
+/-/CC
vs./CC
-/-/JJ
)/)
using/VBG
PLINK/NN
./.
====================
Association/NN
of/IN
LPL/NN
SNPs/NNS
with/IN
lipid/NN
concentrations/NNS
====================
We/PRP
sequentially/RB
discarded/VBD
6/CD
SNPs/NNS
with/IN
MAF/NN
</JJR
0.05/CD
,/,
2/CD
SNPs/NNS
with/IN
call/JJ
rate/NN
</JJR
95/CD
%/NN
,/,
and/CC
1/CD
SNP/NN
with/IN
HWE/NN
p-value/JJ
</JJR
0.002/CD
,/,
leaving/VBG
19/CD
SNPs/NNS
for/IN
the/DT
association/NN
study/NN
at/IN
stage/NN
1/CD
./.
====================
Our/PRP$
results/NNS
show/VBP
that/IN
SNPs/NNS
located/JJ
in/IN
the/DT
LPL/NN
gene/NN
,/,
including/VBG
the/DT
3/CD
'/``
flanking/JJ
region/NN
,/,
were/VBD
strongly/RB
associated/VBN
with/IN
HDLC/NN
and/CC
TG/NN
levels/NNS
./.
====================
The/DT
linear/JJ
regression/NN
,/,
adjusted/VBN
for/IN
age/NN
,/,
gender/RB
,/,
and/CC
BMI/NN
,/,
using/VBG
combined/JJ
data/NNS
from/IN
the/DT
two/CD
study/NN
stages/NNS
,/,
revealed/VBD
that/IN
15/CD
SNPs/NNS
were/VBD
associated/VBN
with/IN
HDLC/NN
and/CC
TG/NN
levels/NNS
(/(
Table/JJ
2/CD
)/)
./.
====================
The/DT
strongest/JJS
associations/NNS
were/VBD
between/IN
rs10503669/NN
and/CC
both/CC
HDLC/NN
(/(
combined/JJ
p/NN
=/JJ
3.6/CD
×/CD
10-22/CD
;/:
2.2-mg/dL/RB
increase/VBP
per/IN
minor/JJ
T/NN
allele/NN
)/)
and/CC
TG/NN
(/(
combined/JJ
p/NN
=/JJ
3/CD
×/NN
10-15/CD
;/:
13.6-mg/dL/RB
decrease/NN
per/IN
minor/JJ
T/NN
allele/NN
)/)
in/IN
additive/JJ
models/NNS
./.
====================
However/RB
,/,
no/DT
strong/JJ
association/NN
was/VBD
detected/VBN
between/IN
the/DT
SNP/NN
and/CC
either/CC
LDLC/NN
or/CC
TCHL/NN
levels/NNS
(/(
Supplementary/JJ
Fig/NN
./.
====================
1/CD
)/)
./.
====================
For/IN
LPL/NN
SNPs/NNS
,/,
we/PRP
tested/VBD
2/CD
intronic/JJ
SNPs/NNS
and/CC
2/CD
SNPs/NNS
located/JJ
in/IN
the/DT
3/CD
'/``
untranslated/JJ
region/NN
(/(
UTR/NN
)/)
from/IN
stage/NN
1/CD
./.
====================
Of/IN
these/DT
,/,
two/CD
SNPs/NNS
in/IN
the/DT
3/CD
'/``
UTR/NN
(/(
rs11570892/NN
and/CC
rs3200218/NN
)/)
were/VBD
not/RB
significantly/RB
associated/VBN
with/IN
any/DT
lipid/NN
concentration/NN
(/(
Supplementary/JJ
Table/JJ
1/CD
)/)
./.
====================
Two/CD
intronic/JJ
SNPs/NNS
,/,
rs263/RB
and/CC
rs271/NN
,/,
were/VBD
significantly/RB
associated/VBN
to/TO
higher/JJR
HDLC/NN
levels/NNS
(/(
p/NN
=/JJ
1.2/CD
×/RB
10-10/CD
and/CC
p/NN
=/JJ
2.5/CD
×/NNP
10-11/CD
;/:
1.2-/CD
and/CC
1.3-mg/dL/JJ
increase/VBP
per/IN
minor/JJ
A/DT
and/CC
T/NN
allele/NN
,/,
respectively/RB
)/)
and/CC
lower/JJR
TG/NN
levels/NNS
(/(
p/NN
=/JJ
1.7/CD
×/NNP
10-6/CD
and/CC
p/NN
=/JJ
7.2/CD
×/NNP
10-7/CD
;/:
8.8-/RB
and/CC
9-mg/dL/JJ
decrease/NN
per/IN
minor/JJ
A/DT
and/CC
T/NN
allele/NN
,/,
respectively/RB
)/)
(/(
Table/JJ
2/CD
)/)
./.
====================
In/IN
stage/NN
2/CD
,/,
7/CD
intronic/JJ
SNPs/NNS
and/CC
2/CD
SNPs/NNS
that/DT
were/VBD
located/JJ
in/IN
the/DT
3/CD
'/``
UTR/NN
were/VBD
tested/VBN
./.
====================
It/PRP
was/VBD
found/VBN
that/IN
rs263/RB
and/CC
rs271/NN
were/VBD
also/RB
strongly/RB
associated/VBN
with/IN
increased/VBN
HDLC/NN
(/(
p/NN
=/JJ
5.5/CD
×/NNP
10-6/CD
and/CC
p/NN
=/JJ
5.1/CD
×/NNP
10-6/CD
,/,
respectively/RB
;/:
both/DT
showed/VBD
a/DT
1.5-mg/dL/JJ
increase/VBP
per/IN
minor/JJ
A/DT
and/CC
T/NN
allele/NN
)/)
(/(
Table/JJ
2/CD
)/)
and/CC
decreased/VBD
TG/NN
levels/NNS
(/(
p/NN
=/JJ
3.3/CD
×/RB
10-3/CD
and/CC
p/NN
=/JJ
2.2/CD
×/NNP
10-3/CD
;/:
8.6-/RB
and/CC
8.7-mg/dL/JJ
decrease/NN
per/IN
minor/JJ
A/DT
and/CC
T/NN
allele/NN
,/,
respectively/RB
)/)
./.
====================
Additionally/RB
,/,
4/CD
intronic/JJ
SNPs/NNS
(/(
rs253/RB
,/,
rs326/RB
,/,
rs327/RB
,/,
and/CC
rs12679834/RB
)/)
were/VBD
significantly/RB
associated/VBN
with/IN
increased/VBN
HDLC/NN
(/(
p/NN
=/JJ
4.2/CD
×/RB
10-3/CD
,/,
p/NN
=/JJ
1.5/CD
×/RB
10-9/CD
,/,
p/NN
=/JJ
1.6/CD
×/RB
10-9/CD
and/CC
p/NN
=/JJ
3.1/CD
×/RB
10-14/CD
;/:
increase/RB
of/IN
0.8/CD
,/,
2.1/CD
,/,
2.1/CD
,/,
and/CC
3.3/CD
mg/dL/NN
per/IN
minor/JJ
allele/NN
,/,
respectively/RB
)/)
and/CC
decreased/VBD
TG/NN
levels/NNS
(/(
p/NN
=/JJ
3.6/CD
×/RB
10-3/CD
,/,
p/NN
=/JJ
9.1/CD
×/RB
10-7/CD
,/,
p/NN
=/JJ
5.9/CD
×/RB
10-7/CD
and/CC
p/NN
=/JJ
1.3/CD
×/RB
10-6/CD
;/:
increase/RB
of/IN
7.4/CD
,/,
12.2/CD
,/,
12.3/CD
,/,
and/CC
13.7/CD
mg/dL/NN
per/IN
minor/JJ
allele/NN
,/,
respectively/RB
)/)
(/(
Supplementary/NNP
Table/JJ
2/CD
)/)
./.
====================
The/DT
analysis/NN
using/VBG
combined/JJ
data/NNS
from/IN
the/DT
two/CD
stages/NNS
showed/VBD
that/IN
rs263/RB
and/CC
rs271/NN
were/VBD
also/RB
significantly/RB
associated/VBN
with/IN
HDLC/NN
(/(
p/NN
=/JJ
1.7/CD
×/NNP
10-11/CD
and/CC
p/NN
=/JJ
5.7/CD
×/NNP
10-12/CD
,/,
respectively/RB
;/:
increase/RB
in/IN
both/DT
cases/NNS
of/IN
1.2/CD
mg/dL/NN
per/IN
minor/JJ
A/DT
and/CC
T/NN
allele/NN
)/)
and/CC
TG/NN
levels/NNS
(/(
p/NN
=/JJ
6.8/CD
×/NNP
10-7/CD
and/CC
p/NN
=/JJ
2.7/CD
×/NNP
10-7/CD
;/:
decrease/RB
of/IN
8.1/CD
,/,
8.3/CD
mg/dL/NN
per/IN
minor/JJ
A/DT
and/CC
T/NN
allele/NN
,/,
respectively/RB
)/)
(/(
Table/JJ
2/CD
)/)
./.
====================
Association/NN
of/IN
LPL/NN
HTs/NNS
with/IN
lipid/NN
concentration/NN
====================
Two/CD
blocks/VBZ
,/,
including/VBG
SNPs/NNS
located/JJ
in/IN
the/DT
LPL/NN
gene/NN
,/,
were/VBD
identified/VBN
(/(
Supplementary/JJ
Fig/NN
./.
====================
2/CD
)/)
,/,
and/CC
the/DT
association/NN
of/IN
HT/NN
with/IN
lipid/NN
profiles/NNS
for/IN
the/DT
two/CD
blocks/NNS
was/VBD
examined/VBN
./.
====================
The/DT
analysis/NN
using/VBG
combined/JJ
data/NNS
from/IN
the/DT
two/CD
stages/NNS
showed/VBD
that/IN
block/VBP
2/CD
,/,
which/WDT
includes/VBZ
SNPs/NNS
located/JJ
in/IN
the/DT
LPL/NN
gene/NN
,/,
including/VBG
the/DT
3/CD
'/``
flanking/JJ
region/NN
,/,
was/VBD
the/DT
region/NN
most/JJS
strongly/RB
associated/VBN
with/IN
lipid/NN
concentrations/NNS
(/(
Table/JJ
3/CD
)/)
./.
====================
HT3/NN
in/IN
block/VBP
2/CD
was/VBD
strongly/RB
associated/VBN
with/IN
increased/VBN
HDLC/NN
levels/NNS
(/(
p/NN
=/JJ
2.86/CD
×/NNP
10-22/CD
;/:
2.25-mg/dL/RB
increase/VBP
per/IN
HT3/NN
)/)
and/CC
reduced/VBD
TG/NN
levels/NNS
(/(
p/NN
=/JJ
9.09/CD
×/NNP
10-15/CD
;/:
13.7-mg/dL/RB
decrease/NN
per/IN
HT3/NN
)/)
,/,
whereas/IN
HT1/NN
was/VBD
strongly/RB
associated/VBN
with/IN
reduced/VBN
HDLC/NN
levels/NNS
(/(
p/NN
=/JJ
1.1/CD
×/NNP
10-14/CD
;/:
1.2-mg/dL/RB
decrease/NN
per/IN
HT1/NN
)/)
and/CC
higher/JJR
TG/NN
levels/NNS
(/(
p/NN
=/JJ
3.05/CD
×/NNP
10-12/CD
;/:
8.6-mg/dL/NNP
increase/VBP
per/IN
HT1/NN
)/)
./.
====================
There/EX
was/VBD
no/DT
significant/JJ
association/NN
between/IN
HT/NN
and/CC
either/CC
LDLC/NN
or/CC
TCHL/NN
./.
====================
The/DT
analysis/NN
using/VBG
imputed/JJ
data/NNS
also/RB
showed/VBD
a/DT
strong/JJ
association/NN
between/IN
HTs/NNS
and/CC
lipid/NN
levels/NNS
in/IN
the/DT
2/CD
blocks/VBZ
,/,
including/VBG
LPL/NN
SNPs/NNS
(/(
Supplementary/JJ
Table/JJ
3/CD
)/)
./.
====================
HT1/DT
in/IN
block/VBP
2/CD
was/VBD
significantly/RB
associated/VBN
with/IN
a/DT
reduced/JJ
HDLC/NN
level/NN
(/(
p/NN
=/JJ
4.2/CD
×/NNP
10-15/CD
;/:
1.3-mg/dL/RB
decrease/NN
per/IN
HT1/NN
)/)
and/CC
an/DT
increased/VBN
level/NN
of/IN
TG/NN
(/(
p/NN
=/JJ
1.9/CD
×/RB
10-8/CD
;/:
8-mg/dL/RB
increase/VBP
per/IN
HT1/NN
)/)
,/,
whereas/IN
HT3/NN
was/VBD
significantly/RB
associated/VBN
with/IN
increased/VBN
HDLC/NN
(/(
p/NN
=/JJ
7.8/CD
×/RB
10-16/CD
;/:
2-mg/dL/RB
increase/VBP
per/IN
HT3/NN
)/)
and/CC
LDLC/NN
levels/NNS
(/(
p/NN
=/JJ
5.1/CD
×/RB
10-3/CD
;/:
2.3-mg/dL/RB
increases/VBZ
per/IN
HT3/NN
)/)
and/CC
decreased/VBD
TG/NN
levels/NNS
(/(
p/NN
=/JJ
5.6/CD
×/RB
10-13/CD
;/:
15.1-mg/dL/RB
decrease/NN
per/IN
HT3/NN
)/)
./.
====================
Effect/JJ
of/IN
the/DT
interaction/NN
between/IN
polymorphisms/NNS
located/JJ
in/IN
the/DT
LPL/NN
gene/NN
and/CC
lifestyle/JJ
on/IN
lipid/NN
concentration/NN
====================
We/PRP
tested/VBD
LPL/NN
SNPs/NNS
and/CC
HTs/NNS
from/IN
stage/NN
1/CD
./.
====================
All/DT
significant/JJ
associations/NNS
were/VBD
found/VBN
in/IN
the/DT
results/NNS
of/IN
the/DT
dominant/JJ
model/NN
for/IN
the/DT
minor/JJ
allele/NN
./.
====================
The/DT
association/NN
of/IN
minor/JJ
alleles/NNS
for/IN
3/CD
SNPs/NNS
(/(
rs263/CD
,/,
rs271/NN
,/,
rs328/NN
)/)
with/IN
higher/JJR
HDLC/NN
levels/NNS
also/RB
depended/VBD
on/IN
energy/NN
intake/JJ
(/(
Supplementary/JJ
Fig/NN
./.
====================
3/CD
)/)
./.
====================
Of/IN
these/DT
,/,
the/DT
minor/JJ
alleles/NNS
of/IN
2/CD
SNPs/NNS
(/(
rs263/CD
,/,
rs271/NN
)/)
were/VBD
associated/VBN
with/IN
lower/JJR
TG/NN
levels/NNS
,/,
also/RB
depending/VBG
on/IN
energy/NN
intake/JJ
./.
====================
The/DT
association/NN
of/IN
the/DT
minor/JJ
alleles/NNS
of/IN
two/CD
SNPs/NNS
(/(
rs263/CD
,/,
rs271/NN
)/)
with/IN
higher/JJR
HDLC/NN
levels/NNS
also/RB
depended/VBD
on/IN
fat/NN
intake/JJ
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
The/DT
minor/JJ
alleles/NNS
of/IN
2/CD
SNPs/NNS
(/(
rs263/CD
,/,
rs271/NN
)/)
were/VBD
also/RB
associated/VBN
with/IN
higher/JJR
HDLC/NN
levels/NNS
and/CC
lower/JJR
TG/NN
levels/NNS
through/IN
an/DT
interaction/NN
with/IN
cigarette/JJ
smoking/NN
and/CC
with/IN
lower/JJR
TG/NN
levels/NNS
through/IN
an/DT
interaction/NN
with/IN
alcohol/NN
consumption/NN
(/(
Fig/NN
./.
====================
2/CD
,/,
Supplementary/JJ
Fig/NN
./.
====================
4/CD
)/)
./.
====================
Interaction/NN
effects/NNS
of/IN
HT1/NN
and/CC
2/CD
in/IN
block/VBP
1/CD
,/,
which/WDT
were/VBD
formed/VBN
by/IN
two/CD
SNP/NN
(/(
rs271/CD
,/,
rs263/RB
)/)
in/IN
strong/JJ
LD/NN
(/(
r2/NN
=/JJ
0.99/CD
)/)
,/,
with/IN
lifestyle/JJ
factors/NNS
on/IN
HDLC/NN
and/CC
TG/NN
levels/NNS
were/VBD
found/VBN
to/TO
be/VB
almost/RB
same/JJ
with/IN
those/DT
of/IN
rs271/NN
and/CC
rs263/NN
(/(
data/NNS
not/RB
shown/VBN
)/)
./.
====================
In/IN
block/NN
2/CD
,/,
HT3/NN
was/VBD
associated/VBN
with/IN
higher/JJR
HDLC/NN
levels/NNS
and/CC
lower/JJR
TG/NN
levels/NNS
and/CC
depended/VBD
on/IN
an/DT
interaction/NN
with/IN
energy/NN
intake/JJ
(/(
Fig/NN
./.
====================
3/CD
,/,
Supplementary/JJ
Fig/NN
./.
====================
3/CD
)/)
./.
====================
HT4/NN
in/IN
block/NN
2/CD
was/VBD
associated/VBN
with/IN
lower/JJR
TG/NN
levels/NNS
through/IN
an/DT
interaction/NN
with/IN
cigarette/JJ
smoking/NN
(/(
Supplementary/JJ
Fig/NN
./.
====================
4/CD
)/)
./.
====================
For/IN
the/DT
interaction/NN
between/IN
LPL/NN
polymorphisms/NNS
and/CC
physical/JJ
activity/NN
,/,
there/EX
was/VBD
no/DT
significant/JJ
association/NN
with/IN
any/DT
lipid/NN
levels/NNS
./.
====================
The/DT
human/JJ
LPL/NN
gene/NN
is/VBZ
located/JJ
on/IN
chromosome/NN
8p22/NN
and/CC
includes/VBZ
10/CD
exons/NNS
encoding/VBG
475/CD
amino/NN
acids/NNS
,/,
of/IN
which/WDT
448/CD
amino/NN
acids/NNS
are/VBP
part/NN
of/IN
the/DT
mature/JJ
protein/NN
and/CC
27/CD
of/IN
the/DT
signal/NN
peptide/NN
[/(
19/CD
,/,
20/CD
]/)
./.
====================
LPL/NN
has/VBZ
an/DT
essential/JJ
role/NN
in/IN
the/DT
metabolism/NN
of/IN
lipids/NNS
,/,
as/IN
it/PRP
hydrolyzes/VBZ
a/DT
number/NN
of/IN
substrates/NNS
,/,
such/JJ
as/IN
long-/RB
and/CC
short-chain/JJ
glycerides/NNS
and/CC
phospholipids/NNS
in/IN
vitro/FW
,/,
as/IN
well/RB
as/IN
major/JJ
substrates/NNS
,/,
such/JJ
as/IN
CMs/NNS
and/CC
VLDL/NN
in/IN
vivo/FW
[/(
21/CD
]/)
./.
====================
Dysfunction/NN
of/IN
LPL/NN
has/VBZ
been/VBN
reported/VBN
to/TO
be/VB
associated/VBN
with/IN
chylomicronemia/NN
,/,
atherosclerosis/NN
,/,
obesity/NN
,/,
Alzheimer/NN
's/POS
disease/NN
,/,
and/CC
dyslipidemia/NN
[/(
22/CD
]/)
./.
====================
Genetic/JJ
association/NN
studies/NNS
have/VBP
shown/VBN
that/IN
some/DT
SNPs/NNS
located/JJ
in/IN
the/DT
LPL/NN
gene/NN
,/,
including/VBG
the/DT
3/CD
'/``
flanking/JJ
region/NN
,/,
are/VBP
strongly/RB
associated/VBN
with/IN
HDLC/NN
and/CC
TG/NN
levels/NNS
,/,
mostly/RB
in/IN
Europeans/NNS
./.
====================
Specifically/RB
,/,
by/IN
performing/VBG
meta-analyses/NNS
of/IN
genomewide/NN
association/NN
studies/NNS
,/,
Aulchenko/NNP
et/FW
al/JJ
./.
====================
[/(
13/CD
]/)
found/VBN
that/IN
rs2083637/NN
and/CC
rs10096633/NN
were/VBD
associated/VBN
with/IN
HDLC/NN
and/CC
TG/NN
levels/NNS
,/,
and/CC
it/PRP
was/VBD
also/RB
demonstrated/VBD
that/IN
rs325/NN
and/CC
rs10105606/NN
,/,
reported/VBD
by/IN
Waterworth/NN
et/FW
al/JJ
./.
====================
[/(
11/CD
]/)
,/,
and/CC
rs12678919/NN
,/,
reported/VBD
by/IN
Kathiresan/NN
et/FW
al/JJ
./.
====================
[/(
23/CD
]/)
,/,
were/VBD
associated/VBN
with/IN
HDLC/NN
and/CC
TG/NN
levels/NNS
./.
====================
Studies/NNS
using/VBG
the/DT
candidate/NN
gene/NN
approach/NN
,/,
which/WDT
examines/VBZ
the/DT
effects/NNS
of/IN
genetic/JJ
variants/NNS
of/IN
a/DT
putative/JJ
gene/NN
in/IN
an/DT
association/NN
,/,
have/VBP
reported/VBN
that/IN
some/DT
LPL/NN
SNPs/NNS
are/VBP
associated/VBN
with/IN
HDLC/NN
and/CC
TG/NN
levels/NNS
./.
====================
Tang/NN
et/FW
al/JJ
./.
====================
[/(
24/CD
]/)
recently/RB
revealed/VBD
that/IN
rs326/NN
and/CC
rs328/NN
(/(
which/WDT
convert/VBP
serine/NN
to/TO
a/DT
stop/NN
codon/NN
)/)
and/CC
rs13702/NN
are/VBP
associated/VBN
with/IN
HDLC/NN
and/CC
TG/NN
levels/NNS
in/IN
African-Americans/JJ
and/CC
European-American/NN
populations/NNS
./.
====================
Here/RB
,/,
rs263/NN
and/CC
rs271/NN
,/,
located/JJ
,/,
respectively/RB
,/,
in/IN
introns/NNS
5/CD
and/CC
6/CD
,/,
were/VBD
strongly/RB
associated/VBN
with/IN
increased/VBN
HDLC/NN
and/CC
decreased/VBD
TG/NN
levels/NNS
(/(
Table/JJ
2/CD
)/)
./.
====================
The/DT
two/CD
significant/JJ
SNPs/NNS
formed/VBD
an/DT
HT/NN
block/VBP
with/IN
strong/JJ
LD/NN
(/(
r2/NN
=/JJ
0.99/CD
)/)
in/IN
stage/NN
1/CD
,/,
and/CC
rs3200218/NN
,/,
located/JJ
in/IN
the/DT
3/CD
'/``
UTR/NN
,/,
formed/VBD
another/DT
HT/NN
block/VBP
with/IN
15/CD
SNPs/NNS
located/JJ
in/IN
the/DT
3/CD
'/``
flanking/JJ
region/NN
./.
====================
At/IN
stage/NN
2/CD
,/,
nine/CD
SNPs/NNS
in/IN
the/DT
LPL/NN
gene/NN
remained/VBD
after/IN
SNP/NN
filtering/VBG
,/,
out/RP
of/IN
which/WDT
six/CD
were/VBD
significantly/RB
associated/VBN
with/IN
HDLC/NN
levels/NNS
(/(
Supplementary/JJ
Table/JJ
2/CD
)/)
./.
====================
SNPs/NNS
rs343/NN
,/,
rs253/NN
,/,
rs263/NN
,/,
and/CC
rs271/NN
,/,
located/JJ
,/,
respectively/RB
,/,
in/IN
introns/NNS
3/CD
,/,
4/CD
,/,
5/CD
,/,
and/CC
6/CD
,/,
formed/VBD
an/DT
HT/NN
block/VBP
with/IN
moderate/JJ
LD/NN
(/(
r2/NN
>/JJR
0.3/CD
)/)
./.
====================
SNPs/NNS
rs326/NN
,/,
rs327/NN
,/,
rs12679834/NN
,/,
rs11570892n/NN
,/,
and/CC
rs3200218/NN
formed/VBD
another/DT
HT/NN
block/VBP
with/IN
31/CD
SNPs/NNS
located/JJ
in/IN
the/DT
3/CD
'/``
flanking/JJ
region/NN
./.
====================
In/IN
the/DT
two/CD
blocks/NNS
at/IN
stages/NNS
1/CD
and/CC
2/CD
,/,
some/DT
HTs/NNS
were/VBD
found/VBN
to/TO
be/VB
strongly/RB
associated/VBN
with/IN
HDLC/NN
and/CC
TG/NN
levels/NNS
(/(
Supplementary/JJ
Tables/NNS
4/CD
and/CC
5/CD
)/)
./.
====================
The/DT
analysis/NN
using/VBG
the/DT
combined/JJ
data/NNS
from/IN
both/CC
stages/NNS
showed/VBD
that/IN
HTs/NNS
were/VBD
also/RB
significantly/RB
associated/VBN
with/IN
HDLC/NN
and/CC
TG/NN
levels/NNS
(/(
Table/JJ
3/CD
)/)
./.
====================
Using/VBG
the/DT
imputation/NN
data/NNS
,/,
we/PRP
found/VBD
that/IN
more/RBR
LPL/NN
SNPs/NNS
were/VBD
included/VBN
in/IN
the/DT
two/CD
blocks/NNS
./.
====================
HTs/NNS
that/DT
were/VBD
significantly/RB
associated/VBN
with/IN
lipid/NN
profiles/NNS
were/VBD
also/RB
identified/VBD
(/(
Supplementary/JJ
Table/JJ
3/CD
)/)
./.
====================
The/DT
strongest/JJS
association/NN
of/IN
HT/NN
with/IN
HDLC/NN
and/CC
TG/NN
levels/NNS
was/VBD
observed/VBN
in/IN
block/NN
2/CD
(/(
from/IN
both/CC
stages/NNS
)/)
./.
====================
A/DT
previous/JJ
study/NN
reported/VBD
that/IN
one/CD
HT/NN
was/VBD
associated/VBN
with/IN
increased/VBN
LPL/NN
activity/NN
[/(
25/CD
]/)
./.
====================
The/DT
HT/NN
was/VBD
found/VBN
to/TO
be/VB
consistent/JJ
with/IN
HT3/NN
in/IN
block/VBP
2/CD
,/,
found/VBN
using/VBG
stage/NN
1/CD
and/CC
imputed/VBD
data/NNS
,/,
which/WDT
was/VBD
associated/VBN
here/RB
with/IN
increased/VBN
HDLC/NN
and/CC
decreased/VBD
TG/NN
levels/NNS
./.
====================
In/IN
block/NN
2/CD
,/,
we/PRP
found/VBD
that/IN
one/CD
SNP/NN
,/,
rs328/NN
,/,
which/WDT
converts/VBZ
serine/NN
to/TO
a/DT
stop/NN
codon/NN
,/,
was/VBD
included/VBN
using/VBG
imputed/JJ
data/NNS
./.
====================
Interestingly/RB
,/,
the/DT
minor/JJ
allele/NN
G/NN
of/IN
rs328/NN
was/VBD
found/VBN
only/RB
in/IN
HT3/NN
./.
====================
It/PRP
has/VBZ
been/VBN
reported/VBN
that/IN
this/DT
minor/JJ
allele/NN
is/VBZ
associated/VBN
with/IN
increased/VBN
HDLC/NN
and/CC
decreased/VBD
TG/NN
concentrations/NNS
in/IN
Japanese/JJ
[/(
26/CD
]/)
and/CC
European/JJ
populations/NNS
[/(
10/CD
,/,
27/CD
]/)
,/,
and/CC
our/PRP$
results/NNS
support/VBP
this/DT
finding/NN
./.
====================
This/DT
truncated/VBN
variant/JJ
was/VBD
also/RB
demonstrated/VBD
to/TO
have/VB
higher/JJR
catalytic/JJ
activity/NN
[/(
28-30/CD
]/)
./.
====================
SNP/NN
rs328/NN
has/VBZ
been/VBN
reported/VBN
to/TO
be/VB
in/IN
strong/JJ
LD/NN
with/IN
rs17482753/NN
in/IN
European/JJ
(/(
r2/NN
=/JJ
1/CD
)/)
and/CC
African/JJ
(/(
r2/NN
=/JJ
0.852/CD
)/)
populations/NNS
[/(
31/CD
]/)
./.
====================
rs17482753/RB
was/VBD
genotyped/VBN
in/IN
stage/NN
1/CD
and/CC
2/CD
of/IN
this/DT
study/NN
,/,
and/CC
the/DT
SNP/NN
was/VBD
found/VBN
to/TO
be/VB
in/IN
strong/JJ
LD/NN
with/IN
rs328/NN
,/,
according/VBG
to/TO
the/DT
imputed/JJ
data/NNS
(/(
r2/NN
=/JJ
0.993/CD
)/)
./.
====================
We/PRP
additionally/RB
identified/VBN
strong/JJ
LD/NN
(/(
r2/NN
=/JJ
0.93/CD
)/)
between/IN
rs328/NN
and/CC
rs17482753/NN
by/IN
using/VBG
genotype/JJ
data/NNS
of/IN
830/CD
Korean/JJ
participants/NNS
obtained/VBN
from/IN
a/DT
previous/JJ
study/NN
[/(
32/CD
]/)
,/,
in/IN
which/WDT
samples/NNS
in/IN
stage/NN
1/CD
of/IN
this/DT
study/NN
were/VBD
included/VBN
./.
====================
Similar/JJ
to/TO
the/DT
results/NNS
of/IN
rs328/NN
obtained/VBN
using/VBG
the/DT
imputed/JJ
data/NNS
in/IN
this/DT
study/NN
,/,
the/DT
rs17482753/NN
minor/JJ
allele/NN
was/VBD
found/VBN
to/TO
be/VB
strongly/RB
associated/VBN
with/IN
raised/VBN
HDLC/NN
and/CC
reduced/VBD
TG/NN
levels/NNS
in/IN
a/DT
dominant/JJ
manner/NN
at/IN
both/CC
stages/NNS
./.
====================
In/IN
a/DT
previous/JJ
study/NN
,/,
LPL/NN
SNPs/NNS
located/JJ
in/IN
the/DT
3/CD
'/``
UTR/NN
region/NN
were/VBD
considered/VBN
possible/JJ
targets/NNS
affecting/VBG
miRNA/JJ
binding/VBG
sites/NNS
,/,
and/CC
5/CD
SNPs/NNS
were/VBD
predicted/VBN
to/TO
be/VB
putative/JJ
miRNA/JJ
binding/VBG
sites/NNS
by/IN
polymiRTS/NNS
[/(
33/CD
]/)
./.
====================
The/DT
3/CD
'/``
UTR/NN
region/NN
of/IN
the/DT
LPL/NN
gene/NN
was/VBD
included/VBN
in/IN
block/VBP
2/CD
in/IN
this/DT
study/NN
,/,
and/CC
two/CD
of/IN
the/DT
predicted/VBN
5/CD
SNPs/NNS
were/VBD
tested/VBN
(/(
Supplementary/JJ
Table/JJ
1/CD
)/)
./.
====================
Rs1059611/NN
major/JJ
allele/NN
T/NN
from/IN
the/DT
imputed/JJ
data/NNS
was/VBD
significantly/RB
associated/VBN
with/IN
reduced/VBN
levels/NNS
of/IN
HDLC/NN
and/CC
LDLC/NN
and/CC
with/IN
increased/VBN
TG/NN
levels/NNS
in/IN
an/DT
additive/JJ
manner/NN
./.
====================
In/IN
this/DT
SNP/NN
,/,
the/DT
major/JJ
T/NN
allele/NN
was/VBD
predicted/VBN
to/TO
create/VB
a/DT
new/JJ
miRNA/NN
(/(
miR-136/NN
)/)
binding/NN
site/NN
,/,
causing/VBG
abnormal/JJ
repression/NN
of/IN
this/DT
gene/NN
./.
====================
The/DT
major/JJ
allele/NN
of/IN
another/DT
SNP/NN
,/,
rs11570892/NN
,/,
was/VBD
predicted/VBN
to/TO
disrupt/VB
a/DT
conserved/VBN
miRNA/NN
(/(
miR-592/NN
)/)
binding/NN
site/NN
,/,
and/CC
this/DT
could/MD
cause/VB
abnormal/JJ
control/NN
of/IN
normal/JJ
repression/NN
./.
====================
However/RB
,/,
this/DT
SNP/NN
showed/VBD
inconsistent/JJ
association/NN
with/IN
LDLC/NN
levels/NNS
in/IN
stages/NNS
1/CD
and/CC
2/CD
of/IN
this/DT
study/NN
./.
====================
Some/DT
environmental/JJ
factors/NNS
have/VBP
been/VBN
suggested/VBN
to/TO
be/VB
associated/VBN
with/IN
lipid/NN
profiles/NNS
./.
====================
Physical/JJ
activity/NN
was/VBD
reported/VBN
to/TO
be/VB
associated/VBN
with/IN
higher/JJR
HDLC/NN
and/CC
lower/JJR
TG/NN
and/CC
TCHL/NN
concentrations/NNS
[/(
34/CD
]/)
,/,
whereas/IN
smoking/NN
was/VBD
reported/VBN
to/TO
be/VB
associated/VBN
with/IN
higher/JJR
LDLC/NN
and/CC
TG/NN
and/CC
lower/JJR
HDLC/NN
levels/NNS
[/(
35/CD
,/,
36/CD
]/)
./.
====================
Alcohol/NN
consumption/NN
was/VBD
suggested/VBN
to/TO
be/VB
associated/VBN
with/IN
increased/VBN
HDLC/NN
levels/NNS
[/(
37/CD
,/,
38/CD
]/)
,/,
whereas/IN
excessive/JJ
alcohol/NN
consumption/NN
was/VBD
associated/VBN
with/IN
a/DT
higher/JJR
TG/NN
level/NN
[/(
39/CD
]/)
./.
====================
A/DT
low/JJ
fat/NN
intake/JJ
,/,
in/IN
turn/NN
,/,
was/VBD
associated/VBN
with/IN
reduced/VBN
TCHL/NN
,/,
LDLC/NN
,/,
and/CC
HDLC/NN
and/CC
increased/VBD
TG/NN
levels/NNS
[/(
40/CD
]/)
./.
====================
Some/DT
LPL/NN
SNPs/NNS
have/VBP
also/RB
been/VBN
shown/VBN
to/TO
be/VB
associated/VBN
with/IN
lipid/NN
profiles/NNS
through/IN
their/PRP$
interaction/NN
with/IN
smoking/NN
,/,
alcohol/NN
consumption/NN
,/,
and/CC
physical/JJ
activity/NN
./.
====================
Specifically/RB
,/,
rs320/NN
has/VBZ
been/VBN
suggested/VBN
to/TO
interact/VB
with/IN
smoking/NN
[/(
41/CD
,/,
42/CD
]/)
and/CC
physical/JJ
activity/NN
[/(
42/CD
]/)
,/,
and/CC
rs1801177/NN
interacts/VBZ
with/IN
physical/JJ
activity/NN
[/(
43/CD
]/)
./.
====================
The/DT
SNP/NN
rs328/NN
,/,
which/WDT
is/VBZ
a/DT
nonsense/JJ
SNP/NN
included/VBD
in/IN
our/PRP$
imputed/JJ
data/NNS
,/,
has/VBZ
been/VBN
associated/VBN
with/IN
HDL/NN
through/IN
its/PRP$
interaction/NN
with/IN
smoking/NN
and/CC
alcohol/NN
consumption/NN
in/IN
females/NNS
but/CC
not/RB
in/IN
males/NNS
[/(
44/CD
]/)
./.
====================
In/IN
a/DT
recent/JJ
study/NN
,/,
however/RB
,/,
the/DT
interaction/NN
of/IN
several/JJ
LPL/NN
SNPs/NNS
,/,
including/VBG
rs328/NN
,/,
with/IN
alcohol/NN
consumption/NN
was/VBD
suggested/VBN
to/TO
have/VB
no/DT
influence/NN
on/IN
HDLC/NN
levels/NNS
[/(
45/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
show/VBP
that/IN
the/DT
effects/NNS
of/IN
some/DT
LPL/NN
polymorphisms/NNS
on/IN
lipid/NN
concentrations/NNS
were/VBD
regulated/VBN
by/IN
several/JJ
environmental/JJ
factors/NNS
./.
====================
Carriers/NNS
of/IN
each/DT
minor/JJ
allele/NN
of/IN
3/CD
SNPs/NNS
(/(
rs263/CD
,/,
rs271/NN
,/,
and/CC
rs328/NN
)/)
were/VBD
associated/VBN
with/IN
slightly/RB
higher/JJR
HDLC/NN
levels/NNS
,/,
depending/VBG
on/IN
an/DT
interaction/NN
with/IN
energy/NN
intake/JJ
./.
====================
This/DT
effect/NN
,/,
however/RB
,/,
was/VBD
not/RB
observed/VBN
among/IN
non-carriers/NNS
(/(
Supplementary/JJ
Fig/NN
./.
====================
3/CD
)/)
./.
====================
In/IN
two/CD
of/IN
these/DT
SNPs/NNS
(/(
rs263/CD
and/CC
rs271/NN
)/)
,/,
which/WDT
were/VBD
in/IN
strong/JJ
LD/NN
(/(
r2/NN
=/JJ
0.99/CD
in/IN
stages/NNS
1/CD
and/CC
2/CD
)/)
,/,
each/DT
major/JJ
genotype/NN
carrier/NN
led/VBD
to/TO
higher/JJR
levels/NNS
of/IN
TG/NN
,/,
whereas/IN
the/DT
TG/NN
levels/NNS
of/IN
each/DT
minor/JJ
allele/NN
carrier/NN
were/VBD
not/RB
affected/VBN
by/IN
a/DT
higher/JJR
energy/NN
intake/JJ
./.
====================
Carriers/NNS
of/IN
each/DT
minor/JJ
allele/NN
,/,
but/CC
not/RB
non-carriers/NNS
,/,
led/VBD
to/TO
a/DT
higher/JJR
HDLC/NN
level/NN
through/IN
an/DT
interaction/NN
with/IN
a/DT
higher/JJR
intake/NN
of/IN
fat/JJ
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Each/DT
major/JJ
genotype/NN
carrier/NN
of/IN
two/CD
SNPs/NNS
(/(
rs263/CD
and/CC
rs271/NN
)/)
showed/VBD
lower/JJR
HDLC/NN
levels/NNS
and/CC
higher/JJR
TG/NN
levels/NNS
than/IN
minor/JJ
allele/NN
carriers/NNS
through/IN
an/DT
interaction/NN
with/IN
smoking/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
In/IN
the/DT
major/JJ
genotype/NN
carrier/NN
of/IN
these/DT
two/CD
SNPs/NNS
,/,
higher/JJR
TG/NN
levels/NNS
were/VBD
also/RB
found/VBD
by/IN
interacting/VBG
with/IN
alcohol/NN
consumption/NN
(/(
Supplementary/JJ
Fig/NN
./.
====================
4/CD
)/)
,/,
whereas/IN
each/DT
minor/JJ
allele/NN
carrier/NN
was/VBD
less/RBR
affected/VBN
than/IN
non-carriers/NNS
by/IN
smoking/VBG
or/CC
alcohol/NN
consumption/NN
./.
====================
For/IN
interactions/NNS
of/IN
HTs/NNS
,/,
blocks/VBZ
1/CD
and/CC
2/CD
were/VBD
shown/VBN
to/TO
interact/VB
with/IN
inconsistent/JJ
lifestyle/JJ
variables/NNS
./.
====================
Interaction/NN
effects/NNS
of/IN
HT1/NN
and/CC
2/CD
in/IN
block/VBP
1/CD
with/IN
lifestyle/JJ
factors/NNS
,/,
which/WDT
were/VBD
formed/VBN
by/IN
the/DT
two/CD
SNPs/NNS
,/,
on/IN
lipid/NN
levels/NNS
were/VBD
almost/RB
same/JJ
with/IN
those/DT
of/IN
rs263/NN
and/CC
rs271/NN
(/(
data/NNS
not/RB
shown/VBN
)/)
./.
====================
In/IN
the/DT
LPL/NN
gene/NN
,/,
61/CD
missense/NN
mutations/NNS
have/VBP
been/VBN
identified/VBN
,/,
and/CC
interestingly/RB
,/,
42/CD
of/IN
them/PRP
are/VBP
located/JJ
in/IN
exons/NNS
5/CD
and/CC
6/CD
,/,
which/WDT
may/MD
be/VB
contained/VBN
in/IN
block/VBP
1/CD
[/(
46/CD
]/)
./.
====================
Carrier/NN
of/IN
HT3/NN
in/IN
block/VBP
2/CD
,/,
which/WDT
was/VBD
reported/VBN
to/TO
be/VB
associated/VBN
with/IN
increased/VBN
LPL/NN
activity/NN
[/(
25/CD
]/)
,/,
showed/VBD
higher/JJR
HDLC/NN
levels/NNS
and/CC
lower/JJR
TG/NN
levels/NNS
,/,
whereas/IN
non-carriers/NNS
were/VBD
not/RB
affected/VBN
by/IN
a/DT
higher/JJR
energy/NN
intake/JJ
(/(
Fig/NN
./.
====================
3/CD
,/,
Supplementary/JJ
Fig/NN
./.
====================
3/CD
)/)
./.
====================
In/IN
the/DT
non-carrier/JJ
of/IN
HT4/NN
in/IN
block/NN
2/CD
,/,
higher/JJR
TG/NN
levels/NNS
were/VBD
found/VBN
by/IN
interacting/VBG
with/IN
cigarette/JJ
smoking/NN
(/(
Supplementary/JJ
Fig/NN
./.
====================
4/CD
)/)
./.
====================
Smoking/JJ
and/CC
moderate/JJ
alcohol/NN
consumption/NN
were/VBD
reported/VBN
to/TO
be/VB
related/JJ
with/IN
reduced/VBN
and/CC
increased/VBD
LPL/NN
activity/NN
,/,
respectively/RB
[/(
47/CD
,/,
48/CD
]/)
,/,
but/CC
the/DT
precise/JJ
mechanisms/NNS
by/IN
which/WDT
the/DT
interaction/NN
of/IN
LPL/NN
polymorphisms/NNS
with/IN
environmental/JJ
factors/NNS
affects/VBZ
lipid/NN
concentrations/NNS
have/VBP
not/RB
been/VBN
demonstrated/VBN
yet/RB
./.
====================
In/IN
conclusion/NN
,/,
we/PRP
found/VBD
that/IN
HTs/NNS
are/VBP
strongly/RB
associated/VBN
with/IN
HDLC/NN
and/CC
TG/NN
levels/NNS
in/IN
the/DT
2/CD
blocks/VBZ
in/IN
which/WDT
LPL/NN
SNPs/NNS
are/VBP
included/VBD
and/CC
that/IN
SNPs/NNS
in/IN
these/DT
blocks/NNS
are/VBP
also/RB
strongly/RB
associated/VBN
with/IN
HDLC/NN
and/CC
TG/NN
levels/NNS
in/IN
stage/NN
1/CD
./.
====================
Interestingly/RB
,/,
these/DT
results/NNS
were/VBD
replicated/VBN
in/IN
stage/NN
2/CD
,/,
which/WDT
consists/VBZ
of/IN
independent/JJ
samples/NNS
,/,
and/CC
the/DT
combined/JJ
analyses/NNS
,/,
including/VBG
the/DT
samples/NNS
of/IN
stages/NNS
1/CD
and/CC
2/CD
,/,
showed/VBD
the/DT
most/JJS
significant/JJ
results/NNS
./.
====================
Moreover/RB
,/,
by/IN
analyzing/VBG
the/DT
effect/NN
of/IN
the/DT
interaction/NN
of/IN
LPL/NN
polymorphisms/NNS
with/IN
several/JJ
lifestyle/JJ
factors/NNS
on/IN
plasma/NN
lipid/NN
levels/NNS
,/,
we/PRP
have/VBP
shown/VBN
that/IN
the/DT
effects/NNS
of/IN
some/DT
LPL/NN
SNPs/NNS
and/CC
HTs/NNS
on/IN
HDLC/NN
and/CC
TG/NN
concentrations/NNS
are/VBP
regulated/VBN
by/IN
energy/NN
and/CC
fat/NN
intake/JJ
,/,
smoking/VBG
,/,
and/CC
alcohol/NN
consumption/NN
./.
====================
Since/IN
these/DT
results/NNS
have/VBP
not/RB
been/VBN
reported/VBN
in/IN
any/DT
previous/JJ
studies/NNS
,/,
they/PRP
are/VBP
novel/JJ
findings/NNS
./.
====================
These/DT
interaction/NN
effects/NNS
suggest/VBP
that/IN
the/DT
appropriate/JJ
lifestyle/JJ
of/IN
each/DT
individual/JJ
could/MD
be/VB
recommended/VBN
according/VBG
to/TO
the/DT
type/NN
of/IN
LPL/NN
polymorphism/NN
./.
====================
These/DT
results/NNS
should/MD
be/VB
confirmed/VBN
in/IN
other/JJ
populations/NNS
and/CC
in/IN
a/DT
longitudinal/JJ
study/NN
./.
====================
Effect/JJ
of/IN
the/DT
interaction/NN
of/IN
rs271/NN
,/,
which/WDT
was/VBD
in/IN
strong/JJ
linkage/NN
disequilibrium/NN
with/IN
rs263/NN
(/(
r2/NN
=/JJ
0.99/CD
)/)
,/,
with/IN
daily/RB
fat/JJ
intake/JJ
on/IN
high-density/JJ
lipoprotein/NN
cholesterol/NN
(/(
HDLC/NN
)/)
levels/NNS
(/(
p/NN
=/JJ
9.6/CD
×/CD
10-4/CD
)/)
./.
====================
Subjects/NNS
were/VBD
divided/VBN
into/IN
daily/RB
fat/JJ
intake/JJ
≤/NNP
20/CD
g/NN
(/(
TT/NN
or/CC
TC/NN
,/,
774/CD
;/:
CC/NN
,/,
1,314/CD
)/)
,/,
21-30/CD
g/NN
(/(
TT/NN
or/CC
TC/NN
,/,
695/CD
;/:
CC/NN
,/,
1,183/CD
)/)
,/,
31-40/CD
g/NN
(/(
TT/NN
or/CC
TC/NN
,/,
547/CD
;/:
CC/NN
,/,
934/CD
)/)
,/,
and/CC
≥/FW
41/CD
g/NN
(/(
TT/NN
or/CC
TC/NN
,/,
702/CD
;/:
CC/NN
,/,
1,144/CD
)/)
./.
====================
Interaction/NN
p-value/JJ
was/VBD
calculated/VBN
by/IN
linear/JJ
regression/NN
analysis/NN
,/,
which/WDT
includes/VBZ
main/JJ
and/CC
interaction/NN
effects/NNS
,/,
adjusted/VBN
for/IN
residence/NN
area/NN
,/,
age/NN
,/,
gender/NN
,/,
and/CC
body/NN
mass/NN
index/NN
./.
====================
Effect/JJ
of/IN
the/DT
interaction/NN
of/IN
rs271/NN
,/,
which/WDT
was/VBD
in/IN
strong/JJ
linkage/NN
disequilibrium/NN
with/IN
rs263/NN
(/(
r2/NN
=/JJ
0.99/CD
)/)
,/,
with/IN
cigarette/JJ
smoking/VBG
on/IN
high-density/JJ
lipoprotein/NN
cholesterol/NN
(/(
HDLC/NN
)/)
(/(
A/DT
)/)
and/CC
triglyceride/NN
(/(
TG/NN
)/)
(/(
B/NN
)/)
levels/NNS
(/(
p/NN
=/JJ
5.7/CD
×/CD
10-3/CD
and/CC
p/NN
=/JJ
8.60/CD
×/CD
10-3/CD
,/,
respectively/RB
)/)
./.
====================
Subjects/NNS
were/VBD
divided/VBN
into/IN
non-smokers/NNS
(/(
TT/NN
or/CC
TC/NN
,/,
1,629/CD
;/:
CC/NN
,/,
2,689/CD
)/)
and/CC
smokers/NNS
(/(
TT/NN
or/CC
TC/NN
,/,
700/CD
;/:
CC/NN
,/,
1,289/CD
)/)
./.
====================
Interaction/NN
p-values/NNS
were/VBD
calculated/VBN
by/IN
linear/JJ
regression/NN
analyses/NNS
,/,
which/WDT
includes/VBZ
main/JJ
and/CC
interaction/NN
effects/NNS
,/,
adjusted/VBN
for/IN
residence/NN
area/NN
,/,
age/NN
,/,
gender/NN
,/,
and/CC
body/NN
mass/NN
index/NN
./.
====================
Effect/JJ
of/IN
the/DT
interaction/NN
of/IN
haplotype/JJ
3/CD
in/IN
block/VBP
2/CD
(/(
TGTGTAGAGCTCCTCG/NN
)/)
with/IN
daily/RB
energy/NN
intake/JJ
on/IN
high-density/JJ
lipoprotein/NN
cholesterol/NN
(/(
HDLC/NN
)/)
level/NN
(/(
p/NN
=/JJ
5.6/CD
×/CD
10-3/CD
)/)
./.
====================
Subjects/NNS
were/VBD
divided/VBN
into/IN
daily/RB
energy/NN
intake/JJ
≤/NNP
1,500/CD
kcal/JJ
(/(
HT3/HT3/NN
or/CC
HT3/-/JJ
,/,
387/CD
;/:
-/-/JJ
,/,
1,353/CD
)/)
,/,
1,501-2,000/CD
kcal/JJ
(/(
HT3/HT3/NN
or/CC
HT3/-/JJ
,/,
646/CD
;/:
-/-/JJ
,/,
2,297/CD
)/)
,/,
2001-2,500/CD
kcal/JJ
(/(
HT3/HT3/NN
or/CC
HT3/-/JJ
,/,
358/CD
;/:
-/-/JJ
,/,
1,216/CD
)/)
,/,
and/CC
≥/FW
2,501/CD
kcal/JJ
(/(
HT3/HT3/NN
or/CC
HT3/-/JJ
,/,
235/CD
;/:
-/-/JJ
,/,
801/CD
)/)
./.
====================
Interaction/NN
p-values/NNS
were/VBD
calculated/VBN
by/IN
linear/JJ
regression/NN
analyses/NNS
,/,
which/WDT
includes/VBZ
main/JJ
and/CC
interaction/NN
effects/NNS
,/,
adjusted/VBN
for/IN
residence/NN
area/NN
,/,
age/NN
,/,
gender/NN
,/,
and/CC
body/NN
mass/NN
index/NN
./.
====================
HT/NN
,/,
haplotype/NN
./.
====================
Description/NN
of/IN
subjects/NNS
used/VBN
in/IN
stages/NNS
1/CD
and/CC
2/CD
of/IN
the/DT
study/NN
====================
SNPs/NNS
associated/VBN
with/IN
HDLC/NN
and/CC
TG/NN
concentrations/NNS
at/IN
each/DT
stage/NN
of/IN
the/DT
study/NN
====================
Association/NN
between/IN
haplotypes/NNS
,/,
including/VBG
LPL/NN
SNPs/NNS
and/CC
lipid/NN
concentrations/NNS
,/,
using/VBG
combined/JJ
data/NNS
from/IN
stages/NNS
1/CD
and/CC
2/CD
====================
